Joseph Thome
Stock Analyst at TD Cowen
(1.98)
# 2,368
Out of 4,479 analysts
22
Total ratings
40%
Success rate
-4.94%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTE Aerovate Therapeutics | Downgrades: Hold | n/a | $1.73 | - | 2 | Jun 18, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $24.31 | +39.86% | 1 | Jun 17, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $90 | $68.81 | +30.79% | 2 | Apr 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $5.48 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $4.44 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $31.02 | -3.29% | 2 | Mar 1, 2024 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Market Perform | $45 | $41.05 | +9.62% | 2 | Dec 8, 2023 | |
| EVLO Evelo Biosciences | Downgrades: Market Perform | n/a | $0.04 | - | 1 | Oct 18, 2023 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $11.48 | - | 1 | Jan 5, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $37.36 | - | 1 | Dec 12, 2022 | |
| ACRV Acrivon Therapeutics | Initiates: Outperform | n/a | $5.79 | - | 1 | Dec 12, 2022 | |
| THRD Third Harmonic Bio | Initiates: Outperform | n/a | $12.81 | - | 1 | Oct 10, 2022 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $120 → $130 | $80.81 | +60.87% | 2 | Jun 29, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $21.92 | - | 1 | Jan 31, 2022 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | n/a | $14.41 | - | 1 | Nov 23, 2021 | |
| ALLK Allakos | Initiates: Outperform | n/a | $0.89 | - | 1 | Jul 15, 2021 | |
| MRNS Marinus Pharmaceuticals | Initiates: Outperform | n/a | $1.16 | - | 1 | Jul 1, 2020 |
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.73
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $24.31
Upside: +39.86%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $80 → $90
Current: $68.81
Upside: +30.79%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $5.48
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.44
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $31.02
Upside: -3.29%
Cerevel Therapeutics Holdings
Dec 8, 2023
Downgrades: Market Perform
Price Target: $45
Current: $41.05
Upside: +9.62%
Evelo Biosciences
Oct 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.04
Upside: -
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.48
Upside: -
Xenon Pharmaceuticals
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $37.36
Upside: -
Acrivon Therapeutics
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $5.79
Upside: -
Third Harmonic Bio
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.81
Upside: -
Axsome Therapeutics
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $80.81
Upside: +60.87%
Intellia Therapeutics
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $21.92
Upside: -
Entrada Therapeutics
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.41
Upside: -
Allakos
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.89
Upside: -
Marinus Pharmaceuticals
Jul 1, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.16
Upside: -